Search

Copyright of Biotechnology Bulletin is the property of Biotechnology Bulletin Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Biotechnology Bulletin is the property of Biotechnology Bulletin Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Biotechnology Bulletin is the property of Biotechnology Bulletin Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shipin Kexue/ Food Science is the property of Food Science Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effect of trastuzumab combined with elemene injection on the expression of BNP and cTnⅠ in serum of breast cancer. Methods: 78 breast cancer patients treated in our hospital from February 2018 to June 2021 were divided into observation group (n=39) and control group (n=39) according to different treatment drugs. The observation group was treated with trastuzumab combined with elemene injection, and the control group was treated with trastuzumab injection only. The therapeutic effect, preoperative and postoperative T-lymphocyte subsets, quality of life, toxic reactions, serum BNP and cTnⅠ levels were compared between the two groups. Results: (1) The total effective rate of observation group was higher than that of control group (P<0.05). (2) The total incidence of toxicity in observation group was 15.38 %, significantly lower than 35.90 % in control group (P<0.05). (3) After treatment, CD3+ and CD4+ levels in the observation group were higher than those in the control group (P<0.05), while CD8+ levels were lower than those in the control group (P<0.05). (4) After treatment, the serum BNP and cTnⅠ levels increased gradually with the prolongation of treatment cycle, and the serum BNP and cTnⅠ levels in control group were increased compared with observation group in the same cycle (P<0.05). (5) After treatment, the scores of physical function, cognitive function and overall health status in observation group were higher than those in control group(P<0.05). Conclusion: The feasibility of trastuzumab combined with elemene injection in the treatment of breast cancer is good, which can significantly improve the treatment efficiency, improve the quality of life and immune function of patients, and reduce the serum BNP and cTnⅠ levels, which is worthy of clinical application. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)